Protein modulators of resistance to alkylating agents

Details Protein modulators of resistance to alkylating agents Protein modulators of resistance to alkylating agents

2011-01-25

2011-01-25

Long, Scott (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S006120, C977S802000

Reexamination Certificate

active

07875274

ABSTRACT:
There is disclosed a method for identifying a therapeutically responsive phenotype, as distinguished, e.g. from an alkylating agent resistant phenotype in a cell, which method may be used to evaluate the likelihood of successful outcome of treating a tumor cell with an alkylating agent. The method is directed to the NF-κB activation in response to DNA damage caused by alkylating agents. It comprises the step of measuring a level of expression of a protein, which participates in the NF-κB pathway. Preferably it comprises measuring the expression of TNFAIP3 in the cell, wherein a resistant phenotype has less expression of TNFAIP3 than a sensitive phenotype. Another particularly significant gene, which predicts survival, is NFKBIA. Other genes whose altered expression level is associated with resistance or prognosis are TNIP1, TNIP2, RIP, NFKBIB, Beta4GalNAc-T4, NFKBIE, C8orf4, LIF, CD44, FBXO32, and SDC1, and these are also measured in certain embodiments.

REFERENCES:
patent: 5716785 (1998-02-01), Van Gelder et al.
patent: 5807522 (1998-09-01), Brown et al.
patent: 5891636 (1999-04-01), Van Gelder et al.
patent: 6387699 (2002-05-01), Bennett et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6973388 (2005-12-01), Friend et al.
patent: 7171311 (2007-01-01), Dai et al.
patent: 2003/0198961 (2003-10-01), Spelsberg et al.
patent: 2003/0215830 (2003-11-01), Tabiti et al.
patent: 2004/0013691 (2004-01-01), Rosenblum
patent: 2004/0156854 (2004-08-01), Mulligan et al.
patent: 2005/0079496 (2005-04-01), Serfling et al.
patent: 2005/0250137 (2005-11-01), Tainsky et al.
Esteller et al. (N Engl J Med. 2000; 343(19): 1350-1354).
Islaih et al. (Environmental and Molecular Mutagenesis. 2004; 44: 401-419).
Jin et al. (Acta Pharmacologica Sinica. 2004; 25(3): 319-326).
Dudda-Subramanya et al. (Journal of Experimental Therapeutics and Oncology. 2003; 3: 297-304).
Bredel et al. ( Journal of clinical Oncology, Jan. 10, 2006; 24(2): 274-287).
Nakatsu et al. (Mol. Cancer Ther. Mar. 2005; 4(3): 399-412).
Bredel et al. (Journal of Clinical Oncology. Jan. 2006; 24(2): 274-287).
Ningya Shi, et al., “Noninvasive gene targeting to the brain,”PNAS, 2000, vol. 97, No. 13 7567-7572.
Paula Y.P. Lam, et al., “Potential of gene therapy for brain tumors,”Human Molecular Genetics, 2001, vol. 10, 777-787.
Virginia Goss Tusher, et al., “Significance analysis of microarrays applied to the ionizing radiation response,”PNAS, Apr. 24, 2001, vol. 98, No. 9, 5116-5121.
Gary Hardiman, “Microarray Technologies—An Overview,”UC-San Diego,, Mar. 13-15, 2002, 1-5.
William M. Pardridge, et al., “Tyrosine Hydroxylase Replacement in Experimental Parkinson's Disease with Transvascular Gene Therapy,”Journal of the American Society for Experimental NeuroTherapeutics, Jan. 2005, vol. 2, 129-138.
Markus Bredel, et al., “High-Resolution Genome-Wide Mapping of Genetic Alterations in Human Glial Brain Tumors,”Cancer Res, May 15, 2005, vol. 65, No. 10, 4088-4096.
Markus Bredel, et al., “Functional Network Analysis Reveals Extended Gliomagenesis Pathway Maps and Three Novel MYC-Interacting Genes in Human Gliomas,”Cancer Res, Oct. 1, 2005, vol. 65, No. 19, 8679-8689.
Kyle D. Weaver, et al., “Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas,”Journal of Clinical Oncology, Jan. 10, 2006, vol. 24, No. 2, 274-287.
Esteller, et al., “Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents,”New England Journal of Medicine, Nov. 9, 2000, vol. 343, No. 19, 1350-1354.

Affiliated with

Also associated with

Rating

Protein modulators of resistance to alkylating agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein modulators of resistance to alkylating agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein modulators of resistance to alkylating agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2621595